Prior to last Thursday's transaction, YA II CD had held a 4.0% interest in ValiRx.
Shares were down 2.7% on Monday at
Mon, 19th Mar 2018 12:46
Prior to last Thursday's transaction, YA II CD had held a 4.0% interest in ValiRx.
Shares were down 2.7% on Monday at
Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments. The studies on treatment VAL401 were carried out by Valiseek, Valirx's joint venture company with Tangent Reprofiling, and demonstrate
Read more